Haleon plc (NYSE:HLN) Shares Purchased by GAMMA Investing LLC

GAMMA Investing LLC grew its position in shares of Haleon plc (NYSE:HLN) by 151.3% in the 1st quarter, according to the company in its most recent Form 13F filing with the SEC. The firm owned 6,106 shares of the company’s stock after acquiring an additional 3,676 shares during the quarter. GAMMA Investing LLC’s holdings in Haleon were worth $52,000 as of its most recent filing with the SEC.

Other institutional investors have also modified their holdings of the company. Hexagon Capital Partners LLC boosted its stake in Haleon by 107.3% during the 4th quarter. Hexagon Capital Partners LLC now owns 4,236 shares of the company’s stock valued at $35,000 after purchasing an additional 2,193 shares during the period. Pinnacle Bancorp Inc. raised its holdings in shares of Haleon by 853.4% during the fourth quarter. Pinnacle Bancorp Inc. now owns 4,767 shares of the company’s stock valued at $39,000 after buying an additional 4,267 shares during the last quarter. Tower Research Capital LLC TRC boosted its position in shares of Haleon by 146.8% during the fourth quarter. Tower Research Capital LLC TRC now owns 5,398 shares of the company’s stock worth $44,000 after buying an additional 3,211 shares during the period. SRS Capital Advisors Inc. grew its holdings in Haleon by 456.4% in the 4th quarter. SRS Capital Advisors Inc. now owns 5,458 shares of the company’s stock worth $45,000 after buying an additional 4,477 shares in the last quarter. Finally, Hoxton Planning & Management LLC acquired a new stake in Haleon in the 4th quarter valued at approximately $85,000. Institutional investors own 6.67% of the company’s stock.

Haleon Stock Up 0.8 %

HLN opened at $8.64 on Tuesday. The company has a debt-to-equity ratio of 0.53, a quick ratio of 0.73 and a current ratio of 1.04. The company has a market capitalization of $39.45 billion, a PE ratio of 28.80, a P/E/G ratio of 2.26 and a beta of 0.26. The stock’s fifty day moving average is $8.39 and its 200-day moving average is $8.34. Haleon plc has a one year low of $7.70 and a one year high of $8.96.

Haleon (NYSE:HLN) last issued its quarterly earnings results on Wednesday, May 1st. The company reported $0.12 EPS for the quarter, topping the consensus estimate of $0.11 by $0.01. Haleon had a net margin of 9.68% and a return on equity of 13.17%. The firm had revenue of $3.70 billion for the quarter, compared to analysts’ expectations of $3.71 billion. On average, equities analysts predict that Haleon plc will post 0.46 EPS for the current fiscal year.

Wall Street Analyst Weigh In

Several research analysts have recently issued reports on HLN shares. Argus reissued a “buy” rating on shares of Haleon in a research note on Tuesday, March 26th. HSBC started coverage on shares of Haleon in a research note on Wednesday, April 17th. They set a “buy” rating on the stock. Finally, Berenberg Bank began coverage on shares of Haleon in a research note on Wednesday, June 5th. They issued a “buy” rating for the company. One equities research analyst has rated the stock with a hold rating and four have issued a buy rating to the company’s stock. According to MarketBeat, the stock presently has an average rating of “Moderate Buy”.

Haleon Company Profile

Haleon plc, together with its subsidiaries, engages in the research, development, manufacture, and sale of various consumer healthcare products in North America, Europe, the Middle East, Africa, Latin America, and the Asia Pacific. The company provides oral health products, such as toothpastes, mouth washes, and denture care products under the Sensodyne, Polident, Parodontax, Biotene brands; and vitamins, minerals, and supplements under Centrum, Emergen-C, Caltrate brands.